Project Grant R21CA301237
Award Date 8/8/25
Completion Date 6/30/27
Dollars Obligated $462K
Funding Federal Agency
Awarding Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
- The National Cancer Institute (CFDA 93.396 - Cancer Biology Research) awarded a $237,023 Project Grant to the Icahn School of Medicine at Mount Sinai (ISMMS) to develop a high-throughput single-cell multi-omic profiling method (named "SHARE-ME-SEQ") that can jointly capture gene expression, chromatin accessibility, and DNA methylation in acute myeloid leukemia (AML) samples. This 3-year grant, running from March 1, 2025 to February 29, 2028, aims to significantly improve the...
- This Project Grant award from the Department of Health and Human Services' National Institutes of Health (CFDA 93.310 - Trans-NIH Research Support) will provide $1,257,163.00 to the Icahn School of Medicine at Mount Sinai to develop a humanized monoclonal antibody targeting follicle-stimulating hormone (FSH) for treating Alzheimer's disease and associated health conditions in individuals with Down syndrome. The project aims to first measure FSH levels across the lifespan in mouse models of...
- This federal Project Grant award for $152,816.00, provided by the National Institute of Child Health and Human Development (CFDA 93.865 - Child Health and Human Development Extramural Research), aims to investigate the link between Down's syndrome (trisomy 21) and placentation defects. The research will focus on: Identifying transcriptional differences in implantation-stage trophoblasts between trisomy 21 and euploid induced pluripotent stem cell lines through RNA-sequencing. Assessing the...
- This Project Grant award of $234,000 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to investigate how Down syndrome affects the immune system. Specifically, the project will use a novel single-cell sequencing approach to analyze how the extra copy of chromosome 21 in Down syndrome disrupts the normal regulation of genes involved in the interferon immune response. The goal is to...
- The federal Project Grant award titled "Investigating and Targeting NSD2 Mutation-Driven Leukemia Transformation" is funded by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) in the amount of $484,405.00 with a performance period from September 1, 2025 to August 31, 2030. The grant was awarded to Thomas Jefferson University, doing business as Sidney Kimmel Medical College, a private non-profit academic medical center in Pennsylvania. The project aims to...
- This Project Grant award from the National Institutes of Health (NIH) Trans-NIH Research Support program (CFDA 93.310) provides $388,749 to The Washington University in Missouri to conduct research focused on understanding the impact of clonal hematopoiesis on the aging human bone marrow. The goal is to investigate how these somatic mutations that can drive leukemia exist and interact within the bone marrow niche in cancer-free adults, which may yield insights into how these pre-malignant states...
- The Department of Health and Human Services National Institutes of Health (NIH) awarded a $1,488,578 Project Grant under the Trans-NIH Research Support program (CFDA 93.310) to the University of Wisconsin-Madison to develop humanized mouse models for studying Down syndrome (DS) immune responses. The project aims to: 1) Create DS hypoimmune gene-edited induced pluripotent stem cell lines and differentiate them into cardiovascular cell therapies, assessing in vitro DS immune responses; and 2)...
- This R01 project grant, awarded by the National Institutes of Health (NIH) through the Trans-NIH Research Support program (CFDA 93.310), aims to elucidate how the mobilization of transposable elements (TEs) and alterations in mRNA translation disrupt the function of neural progenitor cells (NPCs) in Down Syndrome (DS). The $1,274,904 award, provided to The Children's Hospital Corporation (doing business as Boston Children's Hospital), will fund a collaborative research initiative to map the TE...
- The Project Grant award of $451,000.00 from the National Institutes of Health (NIH) Trans-NIH Research Support program (CFDA 93.310) is funding research at the University of Texas Southwestern Medical Center (UT Southwestern) to identify genes on human chromosome 21 that contribute to the neurological and developmental impairments associated with Down syndrome. The 2-year project will use CRISPR interference (CRISPRi) technology and induced pluripotent stem cells (iPSCs) derived from individuals...
- This $158,976 Project Grant was awarded by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to The Children's Hospital of Philadelphia (CHOP) to investigate the mechanisms underlying hematopoietic disorders associated with Down syndrome (trisomy 21). The research aims to use a novel human induced pluripotent stem cell system to isolate the individual and synergistic roles of trisomy 21, the GATA1S transcription factor mutation, RUNX1 isoforms, and...